EyePoint Pharmaceuticals recently released positive results from a clinical trial of its experimental drug for age-related macular degeneration (AMD), causing its stock price to nearly triple. The drug, called EYP-1901, is a sustained-delivery treatment that releases medicine gradually over time, potentially extending the time between injections for patients with the most severe form of the condition. The midstage clinical trial showed that EYP-1901 was as effective as the current treatment when injected every six months, compared to injections every two months. Other approved drugs for AMD require monthly or more frequent injections. If approved, EYP-1901 could reduce the treatment burden for patients, particularly elderly patients who rely on regular injections to maintain their vision. EyePoint Pharmaceuticals is also testing the drug for two other retinal conditions affecting diabetic patients. With the market for AMD treatments projected to reach $10 billion annually by 2028, EyePoint hopes that EYP-1901 could become a first-line treatment for wet AMD or be used in combination with other therapies. About 1.5 million Americans suffer from wet AMD, a condition that can lead to severe vision loss if left untreated.